In August 2021, Amol Akhade, an oncologist at Nair Medical Hospital in Mumbai, India, received an e-mail from the Swiss drug manufacturer Roche recommending the use of a drug named atezolizumab to treat a specific kind of breast cancer. Akhade was surprised. That month, Roche had withdrawn the drug for this purpose in the United … Read more
Depression and anxiety are not significantly linked to higher cancer risks for most types, according to a multinational study. While a slight increase in risk was observed for lung and smoking-related cancers among those with depression or anxiety, this was largely mitigated by adjustments for lifestyle factors. Recent research indicates that depression and anxiety do … Read more
In this May 25, 2017 file photo, chemotherapy drugs are administered to a patient at a hospital in Chapel Hill, N.C. Two workhorse chemotherapy drugs are increasingly hard to come by, and Colorado cancer centers are trying to manage the shortages with as little effect on patients as possible. A May survey of 27U.S. cancer … Read more
Approval is based on data from a pivotal clinical trial showing that treatment with LONSURF plus bevacizumab resulted in statistically significant and clinically meaningful improvements in overall survival in patients with previously treated mCRC compared to LONSURF as a single agent PRINCETON, N.J., Aug. 2, 2023 /PRNewswire/ — Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. … Read more
The FDA has approved trifluridine and tipiracil (Lonsurf) plus bevacizumab (Avastin) for patients with metastatic colorectal cancer (mCRC) who were previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; a VEGF inhibitor; and an EGFR inhibitor, if they have RAS wild-type disease.1,2 The regulatory decision is supported by data from the phase 3 SUNLIGHT trial (NCT04737187), … Read more
By Matthew Stenger Posted: 8/2/2023 12:07:00 PM Last Updated: 8/2/2023 11:23:29 AM As reported in The Lancet by Neeraj Agarwal, MD, FASCO, and colleagues, the phase III TALAPRO-2 trial has shown that the addition of talazoparib to enzalutamide improved radiographic progressionfree survival vs enzalutamide alone in the first-line treatment of patients with metastatic castration-resistant prostate … Read more
Turns out, you could slash your risk for certain cancers in the time it takes to listen to your favorite pop song or power walk across the parking lot. Getty Images Reviewed by Dietitian Annie Nguyen, M.A., RD We’ve been told for decades that walking 10,000 steps per dayor racking up 150 minutes of physical … Read more
By The ASCO Post Staff Posted: 8/1/2023 9:22:00 AM Last Updated: 8/1/2023 9:48:24 AM On July 31, the U.S. Food and Drug Administration (FDA) approved dostarlimab-gxly (Jemperli) with carboplatin and paclitaxel followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer that is mismatch repairdeficient (dMMR), as determined by an FDA-approved test, … Read more
Dear Toni, I applied for a long-term care policy but was denied due to having a pacemaker installed in January. The agent who presented the LTC plan suggested that I apply for cancer insurance to help with out-of-pocket cost in case I have cancer issues. I had not applied for long-term care because I do … Read more
Many people know exercise reduces the risk of cancers, including liver, lung, breast, and kidney. But structured exercise is time-consuming, requires significant commitment, and often financial outlay or travel to a gym. These practicalities can make it infeasible for most adults. There is very little research on the potential of incidental physical activity for reducing … Read more